ST Pharm officials are taking a commemorative photo while participating in 'CRISPR MEDiCiNE 2025,' the world's largest gene editing therapy conference held in Copenhagen, Denmark, from the 7th to the 11th (local time). Photo by ST Pharm
ST Pharm announced on the 9th that it will participate in the world's largest gene editing therapeutics conference, 'CRISPR MEDiCiNE 2025,' held in Copenhagen, Denmark, from the 7th to the 11th (local time), to promote its new technologies.
CRISPR MEDiCiNE 2025 is a prestigious conference where experts in the global CRISPR medical field gather to discuss the latest advancements and clinical applications of gene editing technology.
At this conference, ST Pharm plans to introduce its competitiveness in the new CRISPR therapeutics field through three poster presentations: ▲Leveraging of circular RNA synthesis in CRISPR-based therapeutics ▲Innovations of process development: From oligonucleotides to guide RNA optimization using PAT and modeling ▲Accelerating cost-efficient xRNA therapeutics research with noble ionizable lipid (STLNP®) and capping reagent (SmartCap®) technologies.
According to recent R&D trends, gene therapies are receiving high attention because they can increase the possibility of complete cure by directly modifying the causative genes of diseases. Gene therapy development is underway in areas such as hereditary rare diseases, cancer, hematologic disorders, and ophthalmic diseases. In particular, advancements in LNP-based delivery technology and RNA stabilization technology are accelerating gene therapy development.
ST Pharm has secured automated processes and ultra-high purity production technologies capable of efficiently synthesizing various oligonucleotides, including gRNA (Guide RNA).
Technologies such as STLNP®, which significantly improve delivery efficiency and safety compared to conventional LNPs, and SmartCap® technology, which enhances RNA stability and efficiency, are expected to maximize the effectiveness of CRISPR therapeutics. Given recent requests from multiple clients for gRNA production, ST Pharm plans to establish dedicated production facilities starting in the third quarter of this year and provide various services to its clients.
An ST Pharm representative stated, "We see this as an opportunity to introduce ST Pharm's technological capabilities in CRISPR-based RNA therapeutics development to the global market," adding, "We will continue to pioneer new markets based on total solutions from RNA synthesis to delivery and production."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
